InvestorsHub Logo
Followers 4
Posts 47
Boards Moderated 0
Alias Born 03/29/2017

Re: None

Thursday, 12/21/2017 12:24:06 AM

Thursday, December 21, 2017 12:24:06 AM

Post# of 124
“Spark also received the 13th Rare Pediatric Disease Priority Review Voucher, issued by the FDA to incentivize work on rare pediatric diseases. Just 24 hours ago, Ultragenyx sold its voucher to Novartis for a cool $130 million. A voucher can be exchanged for priority review of any drug in the company’s pipeline — an alluring prospect when competition is tight.”

https://medcitynews.com/2017/12/gene-therapies-are-on-fire/?rf=1
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONCE News